|
1
|
Lin F, Pei L, Zhang Q, Han W, Jiang S, Lin Y, Dong B, Cui L, Li M. Ox-LDL induces endothelial cell apoptosis and macrophage migration by regulating caveolin-1 phosphorylation. J Cell Physiol 2018; 233:6683-6692. [PMID: 29323707 DOI: 10.1002/jcp.26468] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2017] [Accepted: 01/05/2018] [Indexed: 12/16/2022]
Abstract
Oxidative low-density lipoprotein (ox-LDL) is a risk factor for atherosclerosis. Ox-LDL leads to endothelial injury in the initial stage of atherosclerosis. In this study, we investigated the role of ox-LDL in endothelial injury and macrophage recruitment. We demonstrated that ox-LDL promoted a dose-dependent phosphorylation of caveolin-1 in human umbilical vein endothelial cells. Phosphorylated caveolin-1 increased ox-LDL uptake. Intracellular accumulation of ox-LDL induced NF-κB p65 phosphorylation, promoted HMGB1 translocation from nucleus to cytoplasm and cytochrome C release from mitochondria to cytoplasm, and activated caspase 3, resulting in cell apoptosis. NF-κB activation also facilitated cavolin-1 phosphorylation and HMGB1 expression. In addition, caveolin-1 phosphorylation favored HMGB1 release and nuclear translocation of EGR1. Nuclear translocation of EGR1 contributed to cytoplasmic translocation of HMGB1. The extracellular HMGB1 induced the migration of PMBC-derived macrophages toward HUVECs in a TLR4-dependent manner. Our results suggested that ox-LDL promoted HUVECs apoptosis and macrophage recruitment by regulating caveolin-1 phosphorylation.
Collapse
Affiliation(s)
- Fei Lin
- Department of Cardiology, Shandong Energy Zibo Mining Group Co., Ltd Central Hospital, Zibo, China
| | - Likai Pei
- Department of Cardiology, Shandong Energy Zibo Mining Group Co., Ltd Central Hospital, Zibo, China
| | - Qingbin Zhang
- Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| | - Weizhong Han
- Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| | - Shiliang Jiang
- Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| | - Yanliang Lin
- Department of Center Laboratory, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| | - Bo Dong
- Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| | - Lianqun Cui
- Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| | - Min Li
- Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China
| |
Collapse
|
|
2
|
Makino J, Ogasawara R, Kamiya T, Hara H, Mitsugi Y, Yamaguchi E, Itoh A, Adachi T. Royal Jelly Constituents Increase the Expression of Extracellular Superoxide Dismutase through Histone Acetylation in Monocytic THP-1 Cells. JOURNAL OF NATURAL PRODUCTS 2016; 79:1137-1143. [PMID: 27049436 DOI: 10.1021/acs.jnatprod.6b00037] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Extracellular superoxide dismutase (EC-SOD) is one of the main SOD isozymes and plays an important role in the prevention of cardiovascular diseases by accelerating the dismutation reaction of superoxide. Royal jelly includes 10-hydroxy-2-decenoic acid (10H2DA, 2), which regulates the expression of various types of genes in epigenetics through the effects of histone deacetylase (HDAC) antagonism. The expression of EC-SOD was previously reported to be regulated epigenetically through histone acetylation in THP-1 cells. Therefore, we herein evaluated the effects of the royal jelly constituents 10-hydroxydecanoic acid (10HDA, 1), sebacic acid (SA, 3), and 4-hydroperoxy-2-decenoic acid ethyl ester (4-HPO-DAEE, 4), which is a derivative of 2, on the expression of EC-SOD in THP-1 cells. The treatment with 1 mM 1, 2, or 3 or 100 μM 4 increased EC-SOD expression and histone H3 and H4 acetylation levels. Moreover, the enrichment of acetylated histone H4 was observed in the proximal promoter region of EC-SOD and was caused by the partial promotion of ERK phosphorylation (only 4) and inhibition of HDAC activities, but not by the expression of HDACs. Overall, 4 exerted stronger effects than 1, 2, or 3 and has potential as a candidate or lead compound against atherosclerosis.
Collapse
Affiliation(s)
- Junya Makino
- Department of Biomedical Pharmaceutics, Laboratory of Clinical Pharmaceutics, and ‡Department of Organic and Medicinal Chemistry, Laboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University , 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Rie Ogasawara
- Department of Biomedical Pharmaceutics, Laboratory of Clinical Pharmaceutics, and ‡Department of Organic and Medicinal Chemistry, Laboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University , 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Tetsuro Kamiya
- Department of Biomedical Pharmaceutics, Laboratory of Clinical Pharmaceutics, and ‡Department of Organic and Medicinal Chemistry, Laboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University , 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Hirokazu Hara
- Department of Biomedical Pharmaceutics, Laboratory of Clinical Pharmaceutics, and ‡Department of Organic and Medicinal Chemistry, Laboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University , 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Yukari Mitsugi
- Department of Biomedical Pharmaceutics, Laboratory of Clinical Pharmaceutics, and ‡Department of Organic and Medicinal Chemistry, Laboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University , 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Eiji Yamaguchi
- Department of Biomedical Pharmaceutics, Laboratory of Clinical Pharmaceutics, and ‡Department of Organic and Medicinal Chemistry, Laboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University , 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Akichika Itoh
- Department of Biomedical Pharmaceutics, Laboratory of Clinical Pharmaceutics, and ‡Department of Organic and Medicinal Chemistry, Laboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University , 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| | - Tetsuo Adachi
- Department of Biomedical Pharmaceutics, Laboratory of Clinical Pharmaceutics, and ‡Department of Organic and Medicinal Chemistry, Laboratory of Pharmaceutical Synthetic Chemistry, Gifu Pharmaceutical University , 1-25-4 Daigaku-nishi, Gifu 501-1196, Japan
| |
Collapse
|
|
3
|
Hattori S, Kamiya T, Hara H, Ninomiya M, Koketsu M, Adachi T. CoCl 2 Decreases EC-SOD Expression through Histone Deacetylation in COS7 Cells. Biol Pharm Bull 2016; 39:2036-2041. [DOI: 10.1248/bpb.b16-00551] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Shuhei Hattori
- Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University
| | - Tetsuro Kamiya
- Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University
| | - Hirokazu Hara
- Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University
| | - Masayuki Ninomiya
- Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University
| | - Mamoru Koketsu
- Department of Chemistry and Biomolecular Science, Faculty of Engineering, Gifu University
| | - Tetsuo Adachi
- Laboratory of Clinical Pharmaceutics, Gifu Pharmaceutical University
| |
Collapse
|